Recurrent vulvar squamous cell carcinoma: Outcomes across the treatment spectrum—Are we making progress?
Bibliographic record
Abstract
e17603 Background: No standard treatment exists for recurrent vulvar squamous cell carcinoma (VSCC) and the prognosis is poor. This retrospective study reports on outcomes of recurrent and progressive VSCC patients (pts) across various treatments. Methods: This was a single-center retrospective cohort study conducted at the Ottawa Hospital (Ottawa, Canada). Pts with histologically proven VSCC treated between 2000-2023 were identified, and the study population comprised pts who either recurred or progressed after/during first-line therapy. Clinicopathologic data were collected, and descriptive statistics were performed according to pt demographics, tumor characteristics and treatment modality. Median progression free survival (PFS) and overall survival (OS) were determined by treatment type. The outcomes of unique cases treated with novel therapies are also highlighted. Results: There were 311 pts with a diagnosis of VSCC. Ninety-five pts with recurrent/progressive disease formed the study population with a median age of 72 years and 52% having at least stage III disease at initial diagnosis according to FIGO 2021 staging. The prevailing treatment at time of diagnosis was surgery (74%), with 40% of pts also undergoing radiation, chemotherapy, or a combination of both. Location of disease progression or recurrence was regional 53 (56%), inguinal 31 (33%) and distant 11(12%). There were 60 pts (63)% who had one recurrence, as well as 18 pts (19%) and 3 pts (3%) with two and three recurrences, respectively. Of all patients, 14/95 (15%) showed evidence of early progression following treatment. Treatment for first recurrence included: radiation (18.9%), surgery (16.8%), no treatment (16.8%), chemotherapy (11.6%), chemoradiation (9.4%), surgery with radiation (7.3%) surgery and chemoradiation (2.1%), surgery and chemotherapy (1.1%), and investigational therapy (1.1%). The most common chemotherapy regimen used was cisplatin, while the predominant surgical procedure performed was radical vulvectomy. Two pts received Pembrolizumab for treatment of recurrent disease. One pt received a combination of carboplatinum, paclitaxel and bevacizumab followed by maintenance pembrolizumab for 55 cycles (PFS 27.1 months, mo). A second pt was treated for a second recurrence with carbo-taxol followed by single agent pembrolizumab for 27 cycles with stable disease (PFS 15.7 mo). The mPFS after treatment of first recurrence was 11.6 mo for surgery, 8.7 mo for radiation, 8 mo for chemotherapy, 3.2 mo for chemoradiation, and 2.2 mo for no treatment. Among VSCC pts with recurrent or progressive disease, the median OS from all causes was 21 mo. Conclusions: Pts with recurrent/progressive VSCC who underwent surgery had the most favorable outcomes. Significant promise was shown with pembrolizumab and highlights the need for immunotherapy clinical trials for this rare and fatal woman’s cancer.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.005 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.001 | 0.002 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.000 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".